Home/Pipeline/Undisclosed MASH Program

Undisclosed MASH Program

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

DiscoveryActive

Key Facts

Indication

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Phase

Discovery

Status

Active

Company

Syndya Therapeutics

About Syndya Therapeutics

Syndya Therapeutics is a private, pre-clinical stage biotech founded in 2019 and based in Schlieren, Switzerland. The company leverages a proprietary 3D combinatorial, phenotypic screening platform to discover novel drug combinations targeting complex diseases like MASH and obesity. Under the leadership of CEO Jan Lichtenberg, who has a strong background in phenotypic screening and company creation, Syndya is in stealth mode, actively seeking partners and investors to advance its pipeline. Its approach aims to tackle the multifactorial nature of metabolic diseases through innovative combination therapies.

View full company profile

Therapeutic Areas

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Obesity

Other Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs

Drug	Company	Phase	Status
NGM831 (MK-3655)	NGM Biopharmaceuticals	Phase 2b	Active (Merck-led)
Pegozafermin (BIO89-100)	89bio	Phase 3	Active
Icosabutate	NorthSea Therapeutics	Phase 3	Active
Oxy210	MAX BioPharma	Preclinical	Active
NA-941	Biomed	Phase 2A	Active
PRO-MSH-001	ProdIgY Biotech	Discovery	Active
Partnered Program	Cellarity	Pre-clinical	Active
Lanifibranor	Hepalys	Phase 1	Active (Japan development program)
IW-601	ImmuneWalk Therapeutics	Preclinical	Active
ION224 (IONIS-DGAT2Rx)	Ionis Pharmaceuticals	Phase 2b	Active
ALG-055009	Aligos Therapeutics	Phase 2	Active
CM-101	Chemomab Therapeutics	Phase 2a	Completed